Le Lézard
Classified in: Business

The Institutes Acquire Insurance Thought Leadership Assets


MALVERN, Pa., Jan. 28, 2020 /PRNewswire-PRWeb/ -- The Institutes, the leading risk management and insurance knowledge provider, today announced it has acquired the Insurance Thought Leadership (ITL) brand and online publishing assets, including InsuranceThought Leadership.com and the weekly Six Things e-newsletter, from Insurance Thought Leadership, Inc.

"These unique platforms support our goal of advancing knowledge and connections with those interested in risk management and insurance," said Peter Miller, CPCU, president and CEO of The Institutes. "The ITL assets accelerate our global knowledge leadership role in risk management and insurance, especially in the rapidly growing insurtech space."

InsuranceThoughtLeadership.com and Six Things enable growth through innovation by helping subscribers understand drivers transforming the insurance industry. They also create connections that lead to innovation and strategic advantage.

ITL regularly publishes thought leadership on insurance innovation and emerging technology, curating the best ideas from the brightest minds on both its website and via its widely read weekly email newsletter. Paul Carroll will continue to serve as editor-in-chief of ITL and Six Things.

"ITL.com has been a leader in identifying new opportunities and changing behavior in insurance and will be in good hands with The Institutes," said Wayne Allen, CEO of Insurance Thought Leadership, Inc. "Following the sale, we will focus on providing insurance innovation consulting and research services through IE Advisory and Innovator's Edge."

###

About The Institutes | Risk and Insurance Knowledge Group
The Institutes, the leading provider of risk management and insurance knowledge solutions, offer professional designations, including the CPCU® program. In addition, The Institutes provide introductory, foundational, and leadership programs; online and continuing education courses; events and conferences; online and print news platforms; assessment tools; and research reports.

CPCU is a registered trademark of The Institutes. All rights reserved.

 

SOURCE The Institutes


These press releases may also interest you

at 23:00
Tech Innovator Purba Majumder Recognized as One of North America's Top 100 Women Leaders in 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

at 22:30
Blue Owl Capital Hires Australia Future Fund's Deputy Chief Investment Officer Alicia Gregory
Blue Owl Capital Inc. ("Blue Owl") , a leading alternative asset manager, announced today the hiring of Alicia Gregory as a Managing Director based in Sydney.   Alicia brings over 25 years of investing experience with deep relationships and...

at 22:00
Zetrix/MYEG and MaiCapital Ink MoU to Launch Virtual Asset Funds
Zetrix Foundation and MY E.G. Services Berhad ("MYEG") signed a Memorandum of Understanding (MoU) with MaiCapital, a licensed virtual asset manager in Hong Kong, to collaborate on the launch of a virtual asset fund or Hong Kong virtual assets...

at 21:38
GRUPO ELEKTRA ANNOUNCES REVENUE OF Ps.44,562 MILLION AND EBITDA OF Ps.6,363 MILLION IN THE FIRST QUARTER OF 2024
Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA* Latibex: XEKT), Latin America's leading specialty retailer and financial services company, and the largest non-bank provider of...

at 21:30
UPDATE - O2Gold Signs Definitive Agreement for Acquisition of Quebec Gold Mining Exploration Property; Announces Private Placement
O2Gold Inc. (NEX: OTGO.H) ("O2Gold" or the "Company") is pleased to announce that it has entered into a share exchange agreement dated March 21, 2024 (the "Agreement") with Quebec Aur Ltd., a private Ontario corporation, (the "Target") and its...

at 21:27
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

More news about Business...


News published on and distributed by: